A Phase 1, Single-Center, Open-Label, 2-Arm Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 mg and 60 mg Delayed-Release Capsules in Healthy Chinese Subjects
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole
Study Overview
Brief Summary
The purpose of this study is to assess the pharmacokinetics after a single dose of dexlansoprazole 30 and 60 mg delayed-release capsules in healthy Chinese participants.
Detailed Description
The drug being tested in this study is called Dexlansoprazole. This study will assess the pharmacokinetics, safety and tolerability of a single oral dose of Dexlansoprazole 30 mg and 60 mg delayed-release capsules in healthy participants.
The study will enroll approximately 40 participants, 20 participants in each parallel arm. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:
- Group 1: A single oral dose of Dexlansoprazole 30 mg delayed-release capsule
- Group 2: A single oral dose of Dexlansoprazole 60 mg delayed-release capsule
All participants will be asked to take single dose of study drug on Day 1.
This single center trial will be conducted in China. The overall time to participate in this study is approximately 40 days. Participants will be contacted by telephone or will make a final visit to the clinic 5 to 10 days after receiving their last dose of study drug for a follow-up assessment.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Is a healthy adult man or woman of Chinese descent.
- •Is aged 18 to 45 years, inclusive, at the time of informed consent and study medication dose.
- •Weighs at least 50 kilogram (kg) and has a body mass index (BMI) from 19.0 to 26.0 kilogram per square meter (kg/m^2), inclusive at Screening Visit.
Exclusion Criteria
- •Has a known hypersensitivity to any component of the formulation of dexlansoprazole or other drug with the same mechanism of action (including lansoprazole, omeprazole, esomeprazole, rabeprazole, ilaprazole, or pantoprazole), or related compounds.
- •Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening visit or is unwilling to agree to abstain from alcohol for 48 hours prior to Check-in (Day -1) throughout the confinement and for 48 hours prior to each clinic visit and drugs throughout the study.
- •Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to Check-in (Day -1) or is unwilling to abstain from these products for the duration of the study.
- •Has poor peripheral venous access.
- •Has donated blood products (such as plasma), whole blood or had a significant blood loss (450 millimeter [mL]) within 56 days of Day 1.
Arms & Interventions
Group 1: Dexlansoprazole 30 mg
Dexlansoprazole 30 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
Intervention: Dexlansoprazole (Drug)
Group 2: Dexlansoprazole 60 mg
Dexlansoprazole 60 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
Intervention: Dexlansoprazole (Drug)
Outcomes
Primary Outcomes
Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole
Time Frame: Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Dexlansoprazole
Time Frame: Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Dexlansoprazole
Time Frame: Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose
Secondary Outcomes
No secondary outcomes reported